Noven Once-Daily Lithium For Bipolar Disorder Set Back Following Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to discuss data with FDA before determining a path forward for the drug after it failed to show a statistically significant efficacy benefit.